Let's review the charts and indicators.
Let's take a close look at Gilead Sciences, Regeneron and Eli Lilly.
CRBP has topline Phase 3 data for its primary compound Lenabasum for Systemic Sclerosis due out this summer.
Plus, why shares of vaccine maker Moderna are taking a hit.
Walgreens Boots Alliance lets you collect 4.6% dividend yield, while you wait for the turnaround.
The question is when to buy and what to risk.
Shares of biopharmaceutical manufacturer are close to an upside breakout.
Oxford University, along with Britain's AstraZeneca, published promising data from an early stage trial of a key coronavirus vaccine study Monday in London.
If you are long CVS continue to hold.
BHVN has made a relatively big advance since April and a period of consolidation or sideways price action is probably likely at this time.